Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

SHOCKING: 4 | Mind Blowing Facts

What it means when tech execs warn against 'stifling innovation'

The tech arms race with China is adding a wrinkle, and new fears, to the ongoing debate about regulating AI. And it's providing new ammunition to those who have long advocated to let innovation run wild.

Fortune

Bill Gurley warns of ‘scary’ regulatory capture efforts in the A.I space, hails open-source efforts

A.I. incumbents see open-source models as "their biggest threat" and are turning to lawmakers to fight it, said the venture capitalist.

Fortune

How VC Headline notched a 30% stake in Brazil’s biggest startup acquisition in 5 years

The investor behind Pismo talks about the $1 billion Visa deal and the Latin American deal landscape.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

Legendary VC Bill Gurley opens up about stepping back from Benchmark and his next act

The famous VC explains why Steve Martin inspired him to retire from day to day venture capital, and why if a programmer is not using A.I., “you're probably writing your own death certificate.”

Fortune

Tesla's Master Plan Part 3 May Cost More Than Anticipated Per Benchmark

Tesla certainly has lofty goals thanks to CEO Elon Musk. It would come as no surprise if Master Plan Part 3 proves overly optimistic, but that's how Musk rolls.

InsideEVs

More than 1,000 VC, PE, and investment firms held capital at SVB in 2022

General Catalyst, Two Sigma, and Andreessen Horowitz all kept some portion of their billions in fund assets at the bank.

Fortune

Andreessen Horowitz conquered venture capital without breaking a sweat. Gobbling up the rest of the world won’t be so easy

A16z is betting its startup growth recipe can launch its own business far beyond Silicon Valley. Can its ambitions defy a tanking tech market?

Fortune

Read news from The Economist, FT, and more,
with one subscription

Benzinga's Top Ratings Upgrades, Downgrades For November 10, 2022

Upgrades

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2022

Upgrades

Benzinga

5 Snap Analysts React To Restructuring Plan: 'Attractive Opportunity For Long-Term Holders'

Snap Inc (NYSE: SNAP) shares traded higher by 15% on Wednesday after the social media giant disclosed in a new filing that it will be restructuring its business and laying off 20% of its staff.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 26, 2022

Upgrades

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 11, 2022

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022

Benzinga

Repairing America’s underground infrastructure reveals an unsettled scientific debate

The industry insists that cured-in-place plastic pipe liners are safe. Some scientists say the installation process is not.

Inverse

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2022

Benzinga

8 Snap Analysts React To Q2 Earnings Miss: 'Not Snapping Back Anytime Soon'

Snap Inc (NYSE: SNAP) shares traded lower by 38% on Friday after the company disappointed Wall Street with its second-quarter numbers.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 16, 2022

Upgrades

Benzinga

Why This Netflix Analyst Is Turning Bearish

The impact of continued U.S. dollar strength is not reflected either in Netflix Inc’s (NASDAQ: NFLX) guidance for the second quarter or in the Street projections, according to Benchmark.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022

Upgrades

Benzinga

Benchmark Maintains Buy Rating for Cross Country Healthcare: Here's What You Need To Know

Benchmark has decided to maintain its Buy rating of Cross Country Healthcare (NASDAQ:CCRN) and lower its price target from $42.00 to $37.00. Shares of Cross Country Healthcare are trading down 6.22% over the last 24 hours, at $17.33 per share.

Benzinga

Benchmark Maintains Buy Rating for Zoom Video Comms: Here's What You Need To Know

Benchmark has decided to maintain its Buy rating of Zoom Video Comms (NASDAQ:ZM) and raise its price target from $124.00 to $128.00. Shares of Zoom Video Comms are trading up 5.68% over the last 24 hours, at $94.40 per share.

InsideEVs

More Details On EV Battery Production Forecasts For The Future

Automakers and suppliers are rushing to establish new battery manufacturing facilities. Total lithium-ion capacity has doubled since the beginning of 2021.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022

Upgrades

Benzinga

HSBC Slashes Price Targets On Alibaba, Baidu Due to China's Covid Surge, Regulatory Crackdown

HSBC analyst Charlene Liu cut the price target on Baidu Inc (NASDAQ:BIDU) to $180 from $195 (31.3% upside) and kept a Buy rating on the shares. The analyst now assumes a worse impact from COVID-19 on the company's core ad and cloud businesses and margins, seeing a recovery only in Q4. Liu reduced the price…

Benzinga

UBS Remains Bullish On This Social Media Giant - Read Why

UBS analyst Lloyd Walmsley raised the price target on Meta Platforms Inc (NASDAQ:FB) to $300 from $280 and kept a Buy rating on the shares. The price target implies an upside of 29.4%. The impact of the Russia-Ukraine war is more than offset by the company's lower operating expense estimates. Also Read: From 'Facebook' To 'Meta,' 'Facebookers' To…

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations